JP2012519160A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519160A5
JP2012519160A5 JP2011551465A JP2011551465A JP2012519160A5 JP 2012519160 A5 JP2012519160 A5 JP 2012519160A5 JP 2011551465 A JP2011551465 A JP 2011551465A JP 2011551465 A JP2011551465 A JP 2011551465A JP 2012519160 A5 JP2012519160 A5 JP 2012519160A5
Authority
JP
Japan
Prior art keywords
methyl
ethyl
hetaryl
oxo
methylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011551465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/052079 external-priority patent/WO2010097334A1/de
Publication of JP2012519160A publication Critical patent/JP2012519160A/ja
Publication of JP2012519160A5 publication Critical patent/JP2012519160A5/ja
Pending legal-status Critical Current

Links

JP2011551465A 2009-02-27 2010-02-18 Pde4阻害剤及びnsaidを含有する組み合わせ薬 Pending JP2012519160A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09153855 2009-02-27
EP09153855.3 2009-02-27
EP09166131.4 2009-07-22
EP09166131 2009-07-22
PCT/EP2010/052079 WO2010097334A1 (de) 2009-02-27 2010-02-18 Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids

Publications (2)

Publication Number Publication Date
JP2012519160A JP2012519160A (ja) 2012-08-23
JP2012519160A5 true JP2012519160A5 (enExample) 2013-04-04

Family

ID=41820418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011551465A Pending JP2012519160A (ja) 2009-02-27 2010-02-18 Pde4阻害剤及びnsaidを含有する組み合わせ薬

Country Status (5)

Country Link
US (1) US9161927B2 (enExample)
EP (1) EP2400962B1 (enExample)
JP (1) JP2012519160A (enExample)
CA (1) CA2753604A1 (enExample)
WO (1) WO2010097334A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
EP2215093B1 (de) 2007-10-19 2011-12-14 Boehringer Ingelheim International GmbH Neue piperazino-dihydrothienopyrimidin-derivate
SI2610258T1 (sl) * 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
ES2523169T3 (es) 2008-01-25 2014-11-21 High Point Pharmaceuticals, Llc Compuestos tricíclicos como moduladores de la síntesis de TNF y como inhibidores de PDE4
WO2010097332A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2014066659A1 (en) 2012-10-25 2014-05-01 Tetra Discovery Partners, Llc. Heteroaryl inhibitors of pde4
MX2015009678A (es) 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
WO2016139212A1 (en) * 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
US11365204B2 (en) 2017-09-20 2022-06-21 UNION therapeutics A/S Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115775A1 (en) * 2017-12-15 2019-06-20 Leo Pharma A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115774A1 (en) * 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115776A1 (en) * 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113861189A (zh) 2020-06-29 2021-12-31 Vtv治疗有限责任公司 喹啉衍生物,其药学上可接受的盐及其使用方法
US12545676B2 (en) 2020-07-28 2026-02-10 Vtv Therapeutics Llc Crystalline form of hydrochloride salt of quinoline derivative
JP2025528779A (ja) * 2022-08-09 2025-09-02 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Pde4b阻害剤及びその用途
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
EP4761728A2 (en) * 2023-08-17 2026-06-24 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
CN120398908A (zh) * 2024-02-01 2025-08-01 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162289A2 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂的晶型及其在医药上的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
DE9418068U1 (de) 1994-11-11 1995-01-12 Hoppe AG, 35260 Stadtallendorf Getriebegriff
IL150963A0 (en) * 2000-02-08 2003-02-12 Smithkline Beecham Corp Method and compositions for treating an inflammatory disease
IL160271A0 (en) * 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
WO2005061483A2 (en) 2003-12-23 2005-07-07 Bio-Medisinsk Innovasjon As Modulators of peripheral 5-ht receptors
US20080171746A1 (en) 2005-03-14 2008-07-17 Thomas Klein Method for Preventing Cardiovascular Diseases
WO2007106705A1 (en) 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
HRP20090395T1 (hr) 2006-04-19 2009-08-31 Boehringer Ingelheim International Gmbh Dihidrotienpirimidini za liječenje upalnih bolesti
SI2610258T1 (sl) * 2007-10-19 2014-12-31 Boehringer Ingelheim International Gmbh Substituirani piperidino-dihidrotienopirimidini
WO2010097332A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids

Similar Documents

Publication Publication Date Title
JP2012519159A5 (enExample)
US9161927B2 (en) Drug combinations containing PDE4 inhibitors and NSAIDs
AU2014372166B2 (en) Pharmaceutical combinations
ES2328148T3 (es) Procedimiento para tratar aterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas.
AU2016204638B2 (en) Compositions and methods of treating pulmonary hypertension
JP2013520397A5 (enExample)
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
RU2009131454A (ru) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
RU2015144676A (ru) Применение рецептора антагониста ер4 для лечения хрящевой болезни
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
CA2664413A1 (en) Treatment for non-alcoholic-steatohepatitis
RU2008141509A (ru) Mglur5 модуляторы 1
CA2481535A1 (en) Use of ep4 receptor ligands in the treatment of il-6 involved diseases
JP2016512825A5 (enExample)
JP2012515787A5 (enExample)
CN108430510B (zh) 与中性肽链内切酶的抑制剂(NEP抑制剂)和/或血管紧张素AII拮抗剂组合的可溶性鸟苷酸环化酶(sGC)的刺激剂和/或活化剂及其用途
RU2006137076A (ru) Комбинации, содержащие лиганды рецептора альфа-2-дельта
TW200418798A (en) Selective mGlu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
HUP0401582A2 (hu) Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
RU2015141360A (ru) Ингибиторы тирозинкиназы брутона
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
HRP20210576T1 (hr) 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion, namijenjen liječenju nealkoholne masne bolesti jetre
CN106999482A (zh) 治疗纤维化的方法
BR112014011518A2 (pt) liberação imediata da formulação 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida
AU2012336157A1 (en) Treatment of blood lipid abnormalities and other conditions